ArticleChest2013
Use of selective serotonin reuptake inhibitors and outcomes in pulmonary arterial hypertension.
Article in Chest, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Prevalence, Risk Factors and Intervention for Depression and Anxiety in Pulmonary Hypertension: A Systematic Review and Meta-analysis.Frontiers in medicine · 2022Pooled it
- Article
- Selective Inhibition of Peripheral Serotonin Synthesis in Pulmonary Hypertension.JACC. Basic to translational science · 2024Article
- SSRIs: Applications in inflammatory lung disease and implications for COVID-19.Neuropsychopharmacology reports · 2021Review
- Increased pulmonary serotonin transporter in patients with chronic obstructive pulmonary disease who developed pulmonary hypertension.European journal of nuclear medicine and molecular imaging · 2021Article
- Roles of specific drug therapies for severe pulmonary arterial hypertension in palliative care: a case report.AME case reports · 2021Article
- Anxiety and depression in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Results from a Chinese survey.Experimental and therapeutic medicine · 2020Article
- The burden of comorbidities in pulmonary arterial hypertension.European heart journal supplements : journal of the European Society of Cardiology · 2019Article
- Anxiety and depression in patients with pulmonary hypertension: impact and management challenges.Vascular health and risk management · 2018Review
- Stimulants and Pulmonary Arterial Hypertension: An Update.Advances in pulmonary hypertension · 2018Article
- Future perspectives in pulmonary arterial hypertension.European respiratory review : an official journal of the European Respiratory Society · 2016Review
- DNA Damage and Pulmonary Hypertension.International journal of molecular sciences · 2016Review
- Depression in pulmonary arterial hypertension and interstitial lung diseases.North American journal of medical sciences · 2014Review
- Depression in pulmonary arterial hypertension: An undertreated comorbidity.Lung India : official organ of Indian Chest SocietyReview
- Hemodynamic effects of fluoxetine in pulmonary arterial hypertension: an open label pilot study.Pulmonary circulationArticle
- Platelets, extracellular vesicles and coagulation in pulmonary arterial hypertension.Pulmonary circulationReview
- The serotonin hypothesis in pulmonary hypertension revisited: targets for novel therapies (2017 Grover Conference Series).Pulmonary circulationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundSelective serotonin reuptake inhibitors (SSRIs) have been suggested to offer therapeutic benefit in patients with pulmonary arterial hypertension (PAH). We conducted two analyses to explore the association between SSRI use and PAH outcomes using the Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL Registry).
methodsFirst, new users (SSRI-naive patients who initiated treatment after enrollment, incident use analysis, n = 220) were matched (1:2) with non-SSRI users (nonusers, n = 440) by enrollment center, sex, date of most recent visit, age, and 6-min walk distance. Second, a cross-sectional design was used to compare nonusers (n = 2,463), high-affinity SSRI users (n = 430), and non-high-affinity SSRI users (n = 125) at enrollment. Mortality and a composite end point defined by events indicative of clinical worsening were evaluated.
resultsNew users had a higher risk of death (unadjusted hazard ratio [HR], 1.74; 95% CI, 1.19-2.54; P = .004) and were less likely to be free from the composite end point 2 years after enrollment vs nonusers (25.7% vs 43.2%, respectively; P < .001). Similarly, among prevalent SSRI users (patients with a history of SSRI use at enrollment), high-affinity SSRI users were less likely to be free from the composite end point vs nonusers (unadjusted HR, 1.20; 95% CI, 1.07-1.36; P = .003). In both analyses, differences in outcome were maintained after adjustment for clinical variables previously associated with PAH outcomes.
conclusionsIn a large population of patients with PAH, incident SSRI use was associated with increased mortality and a greater risk of clinical worsening, although we could not adjust for all potential confounders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.